Human antibodies specific for TGFβ2
View Patent ↗Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGFβ) bind specifically isoforms TGFβ2 and TGFβ1 or both, preferentially compared with TGFβ3. Specific binding members may be isolated and utilized in the treatment of disease, particularly fibrotic disease and also immune/inflammatory diseases. Therapeutic utility is demonstrated using in vitro and in vivo models. Full sequence and binding information is provided, including epitope sequence information for particularly advantageous specific binding member which binds the active form of TGFβ2, neutralizing its activity, but does not bind the latent member.
1. An isolated antibody or antibody fragment thereof comprising an antibody-antigen binding domain of a human antibody specific for TGFβ isoform TGFβ2, said antibody-antigen binding domain comprising;
(a) a VH domain selected from the group consisting of the 6H1 VH domain of which the amino acid sequence is shown in FIG. 2( a )(i) (SEQ ID NO: 6), the 11E6 VH domain of which the amino acid sequence is shown in FIG. 2( a )(ii) (SEQ ID NO: 37), the Gold 11-VH domain of which the amino acid sequence is shown in FIG. 2( a )(iii) (SEQ ID NO: 116), the 1-G2 VH domain of which the amino acid sequence is shown in FIG. 2( a )(v) (SEQ ID NO: 120) and the 1-H-6 VH domain of which the amino acid sequence is shown in FIG. 2( a )(vi) (SEQ ID NO: 122); and
(b) a VL domain selected from the group consisting of the 6B1 VL domain of which the amino acid sequence is shown in FIG. 2( b )(iii) (SEQ ID NO:43), the 6H1 VL domain of which the amino acid sequence is shown in FIG. 2( b )(i) (SEQ ID NO: 39), the 6A5 VL domain of which the amino acid sequence is shown in FIG. 2( b )(ii) (SEQ ID NO:41), the 11E6 VL domain of which the amino acid sequence is shown in FIG. 2( b )(iv) (SEQ ID NO:45), the 14F12 VL domain of which the amino acid sequence is shown in FIG. 2( b )(v) (SEQ ID NO:47) and the 6H1 VL domain of which the amino acid sequence is shown in FIG. 2( b )(vi) (SEQ ID NO:124).
2. The antibody or antibody fragment thereof according to claim 1 which is in the form of scFv.
3. The antibody or antibody fragment thereof according to claim 1 which is in the form of a whole antibody.
4. An isolated antibody or antibody fragment thereof comprising an antibody-antigen binding domain of a human antibody specific for TGFβ isoform TGFβ2, said antibody-antigen binding domain comprising;
(a) a VH domain comprising the 6H1 VH domain CDRs shown in FIG. 19(i) , wherein VH CDR1 has the amino acid sequence set forth in SEQ ID NO: 126, VH CDR2 has the amino acid sequence set fort in SEQ ID NO: 127 and VH CDR3 has the amino acid sequence set forth in SEQ ID NO: 128, and
(b) a VL domain comprising VL domain CDRs selected from the group consisting of:
(i) the 6B1 VL domain CDRS shown in FIG. 19 (ii), wherein VL CDR1 has the amino acid sequence set forth in SEQ ID NO: 129, VL CDR2 has the amino acid sequence set fort in SEQ ID NO: 130 and VH CDR3 haste amino acid sequence set forth in SEQ ID NO: 131,
(ii) the 6A5 VL domain CDRs shown in FIG. 19 (iii), wherein VL CDR1 has the amino acid sequence set forth in SEQ ID NO: 132, VL CDR2 has the amino acid sequence set forth in SEQ ID NO: 133, and VH CDR3 has the amino acid sequence set forth in SEQ ID NO: 134, and
(iii) the 6H1 VL CDRs shown in FIG. 19 (iv), wherein VL CDR1 has the amino acid sequence set forth in SEQ ID NO: 135, VL CDR2 has the amino acid sequence set forth in SEQ ID NO: 136, and VH CDR3 has the amino acid sequence set forth in SEQ ID NO: 137.
5. The antibody or antibody fragment thereof according to claim 4 which is in the form of scFv.
6. The antibody or antibody fragment thereof according to claim 4 which is in the form of a whole antibody.
7. The antibody or antibody fragment thereof according to claim 4 wherein the VH domain is the 6H1 VH domain of which the amino acid sequence is shown in FIG. 2( a )(i) (SEQ ID NO: 6).
8. The antibody or antibody fragment thereof according to claim 7 which is in the form of scFv.
9. The antibody or antibody fragment thereof according to claim 7 which is in the form of a whole antibody.
10. The antibody or antibody fragment thereof according to claim 7 wherein the VL domain is selected from the 6B1 VL domain, of which the amino acid sequence is shown in FIG. 2( b )(iii) (SEQ ID NO: 43), the 6H1 VL domain, of which the amino acid sequence is shown in FIG. 2( b )(i) (SEQ ID NO: 124), and the 6A5 VL domain, of which the amino acid sequence is shown in FIG. 2( b )(ii) (SEQ ID NO:41).
11. The antibody or antibody fragment thereof according to claim 10 which is in the form of scFv.
12. The antibody or antibody fragment thereof according to claim 10 which is in the form of a whole antibody.
13. An isolated antibody or antibody fragment thereof comprising an antibody-antigen binding domain of a human antibody specific for TGFβ isoform TGFβ2, said antibody-antigen binding domain comprising;
(a) a VH domain comprising the 6H1 VH domain CDRs shown in FIG. 19(i) , wherein VH CDR1 has the amino acid sequence set forth in SEQ ID NO: 126, VIA CDR2 has the amino acid sequence set forth in SEQ ID NO: 127 and VH CDR3 has the amino acid sequence set forth in SEQ ID NO: 128, and
(b) a VL domain comprising the 6B1 VL domain CDRs shown in FIG. 19 (ii), wherein VL CDR1 has the amino acid sequence set forth in SEQ ID NO: 129, VL CDR2 has the amino acid sequence set forth in SEQ ID NO: 130 and VH CDR3 has the amino acid sequence set forth in SEQ ID NO: 131.
14. The antibody or antibody fragment thereof according to claim 13 which is in the form of scFv.
15. The antibody or antibody fragment thereof according to claim 13 which is in the form of a whole antibody.
16. An isolated antibody or antibody fragment there of comprising an antibody-antigen binding domain of a human antibody specific for TGFβ isoform TGFβ2, said antibody-antigen binding domain comprising the VH domain 6H1 VH of which the amino acid sequence is shown in FIG. 2( a )(i) (SEQ ID NO: 6) and the VL domain 6B1 VL, of which the amino acid sequence is shown in FIG. 2( b )(iii) (SEQ ID NO: 43).
17. The antibody or antibody fragment thereof according to claim 16 which is in the form of scFv.
18. The antibody or antibody fragment thereof according to claim 16 which is in the form of a whole antibody.
19. A composition which comprises an antibody or antibody fragment thereof as in any one of claims 1 , 4 , 7 , 10 , 13 or 16 and an excipient.
20. A pharmaceutical composition comprising an antibody or antibody fragment thereof as in any one of claims 1 , 4 , 7 , 10 , 13 or 16 and a pharmaceutically acceptable excipient.